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Histology of Ewing's sarcoma
A.J. Malcolm
Department ofPathology, Royal Victoria Infirmary,
Newcastle-upon-Tyne, UK.
Ewing, in 1921, described, a new malignant bone tumour
which affected the diaphyses of children and adolescents,
which he called a 'malignant endothelioma'. Since then there
has been mystery and controversy about whether Ewing's
tumour was a distinct entity or merely a useful name for a
group of primitive undifferentiated tumours in bone, which
included metastases from such tumours as neuroblastoma (a
view held by Willis). A malignant tumour composed of
glycogen-rich primitive round cells (Ewing's tumour) is now
accepted as arising in bone, although the cell of origin re-
mains a speculative issue. The descriptions of Ewing's
tumour in the past included cases in which there were poorly-
formed Homer-Wright pseudo-rosettes. At present such
tumours are regarded as being primitive (peripheral) neuro-
ectodermal tumours of bone (PNET). Such tumours react
positively with antibodies to neurone specific enolase (NSE)
and often with S100 protein, and contain neurofilaments.
Electron microscopy shows a few cell processes and
occasional neurosecretory granules. This contrasts with the
more 'classical' Ewing's tumour which fails to react with any
of the 'neural' antibodies and electron microscopy shows cells
having a bland primitive appearance containing only a few
mitochondria, some lipid and some glycogen. There is no
neural differentiation. Between these two extremes there are
tumours described as 'atypical' Ewing's tumour which dis-
play some reactivity with NSE but not with other 'neural'
antibodies. Electron microscopy shows atypical features such
as cell processes but there are not neurosecretory granules.
The so-called 'Askin' tumour is similar but has some definite
neural differentiation. An 11:22 translocation has been
reported in examples of each of these tumours. Some typical
Ewing's tumours have been reported to develop neural
differentiation in tissue culture. This suggests two main pos-
sibilities. Either there is an entity 'Ewing's' tumour and a
distinctly separate tumour which shows varying neural
differentiation called 'PNET' or, alternatively, these tumours
are of common origin but show a spectrum of neural
differentiation ranging from undifferentiated (Ewing's
tumour) to differentiated (PNET). Applying modern
immunological techniques retrospectively to 124 cases shows
that about 25% of previously described Ewing's tumour have
some neural differentiation and might now be called PNETs.
However, there was no significant difference in the site,
radiological features or clinical outcome between these and
Ewing's tumours although all had been treated in an iden-
tical manner.
Gene mapping in relation to the constitutional t(l1;22)
translocation
B.D. Young, S. Nasipuri & F.E. Cotter
ICRF Medical Oncology Laboratory, St Bartholomew's
Hospital, London, UK.
Consistent rearrangements to chromosome 11 at bands q23-
q24 have been reported in a variety of malignancies. The
translocation t(4;1 1)(q21;q23), first reported by Van den
Berghe et al. in (1979), is associated with infantile acute
lymphoblastic leukaemia while the translocations t(9;I 1)
(p22;q23) and t(I 1;19)(q23;pl3) have been observed in cases
of acute monocytic leukaemia. The translocation
t(l 1;22)(q24;q12) is exhibited in 85% of Ewing's sarcoma and
is also seen in neuroepithelioma and Askin tumours.
Although currently there is little information on the
molecular effects of these alterations, it has been established
that the c-ets-J oncogene on chromosome 11 lies distal to the
position of the t(4;11) breakpoint, the t(9;11) breakpoint and
proximal to the t(I1;22) breakpoint in Ewing's sarcoma. The
rare constitutional translocation t(I 1;22) can be distinguished
from the Ewing's sarcoma t(I1;22) by the demonstration of
c-ets-J translocation in the former. A number of genes (in-
cluding Thy-i, T36, and c-ets-1) have been mapped to
1q23 (Human Gene Mapping 9, 1987) but with little in-
formation on their relative positions and no conclusive
evidence of their activation or alteration in such transloca-
tion. It is therefore important to ascertain the positions of
these genes relative to the described translocation.
Current methods of gene mapping are relatively time con-
suming, often involving DNA probe hybridisation to
chromosomes in situ or to DNA from either somatic cell
hybrids or flow-sorted chromosomes. A new approach to
gene mapping has been devised which combines enzymatic
amplification with high-resolution flow-sorting of human
chromosomes. Reliable amplification from as few as 200
chromosomes has been demonstrated. This method, with
particular application to mapping the position of chromo-
somal translocations, has been used to show that the break-
point for the constitutional translocation t(1 1;22)(q23;ql 1)
lies proximal to the genes c-ets-1, Thy-i and T36 and distal
to the int-2 gene. The mapping was confirmed by Southern
analysis to much larger numbers of chromosomes sorted
from the same cell line. Control reactions for the bcl-2 gene
on chromosome 18 and the C gene of the IGH locus on
chromosome 14 demonstrated the discrimination which can
be achieved.
The ability to determine the presence or absence of genes
or DNA fragments in aliquots of small numbers of
chromosomes confers a number of advantages over previous
methods of gene mapping. Firstly, the resolution on a cell
sorter is often improved by decreasing the flow rate of
chromosomes and thus analysis can be performed on smaller
fractions of higher purity than previously obtainable for
spot-blot hybridisation to flow sorted chromosomes. Sec-
ondly the reduced chromosome requirement may open up the
possibility of direct studies on chromosomes from tissue
previously unsuitable for large scale sorting because of lack
of metaphase cells. Studies of Ewing's tumour tissue bearing
translocation involving a common region such as
chromosome llq23-q24 may allow further mapping of the
region by determining the presence or absence of sequences
on the translocated chromosomes. It would be of particular
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interest to examine directly chromosomes from tumour or
leukaemic cells without having to use established cell lines. In
this way it may be possible to detect translocations in cells
without prior knowledge of karyotype status. Following on
from successful amplification from single cells and single
sperm cells this approach potentially could be extended to
amplification from a single flow-sorted chromosome.
The role ofmagnetic resonance imaging (MRI) in Ewing's
sarcoma
F.C. Oliff
Royal Marsden Hospital, Surrey, UK.
The diagnosis of Ewing's sarcoma is made by a combination
of plain film interpretation and histology. The major role of
MRI is that of assessing extent of primary tumour because
the long scan times required prohibit its use for staging
distant metastases and nodal disease. Computed tomography
(CT) is the preferred technique for these purposes.
In studies comparing MRI with CT, MRI has been found
by some to be better at assessing the extent of marrow
disease. The multiplanar imaging of MR allows ready ap-
preciation of the relationship of marrow abnormality to adja-
cent epiphyseal plate and joint. The soft tissue mass can be
identified on T2-weighted images (MR having superior soft
tissue contrast to that of CT), and its relationship to the
neurovascular bundle is demonstrated without the use of
intravenous contrast medium. However, the presence of
peritumoral high signal due to oedema can lead to over-
estimation of tumour extent by as much as 2 cm in the axial
plane.
MRI can also be used to evaluate disease following
therapy. It does not have any advantage over CT when a
simple measurement of tumour size is performed. When sig-
nal intensity of tumour on T2-weighted images was evaluated
in 60 patients with various bone and soft tissue tumours, no
tumour was present in those with low signal (20) (sensitivity
96%) but in those with high signal following surgery (6),
tumour was present in all cases. High signal following
radiotherapy (34) was due to either inflammation or tumour
and differentiation could not be made.
In conclusion, MRI has no role to play in the diagnosis of
Ewing's sarcoma, but is superior to plain films and CT for
staging the primary tumour. It can delineate the extent of
marrow and soft tissue disease but may overestimate tumour
bulk due to peritumoral oedema. On follow-up, the absence
of high signal on T2-weighted images is reassuring. Follow-
ing surgery high signal has been shown to be due to tumour,
but after radiotherapy, differentiation between tumour and
inflammation cannot be made.
Ewing's sarcoma: the St Jude experience 1978-1988
F.A. Hayes, E.I. Thompson, L. Kun, B. Rao, M. Kumar,
W. Myer & H.O. Hustu
St Jude Children's Research Hospital, Memphis, Tennessee,
USA.
In 1978 a protocol for patients with Ewing's sarcoma (ES) of
bone was designed to evaluate (1) the initial response of
previously untreated tumour to cyclophosphamide (Cy) and
adriamycin (Adr) induction chemotherapy, (2) local control
of primary tumours with chemotherapy plus no radiotherapy
(RT) (resected lesions) delayed low-dose (30-50 Gy) limited
port RT (partial clinical responders) and (3) the overall
disease control interval to relatively non-aggressive chemo-
therapy given for 10-12 months duration.
Eighty patients entered this study, 59 with localised disease
and 21 with metastatic tumour. The age range was from 2
years 10 months to 21 years 11 months (median 15 years).
All patients received Cy (150mg m-2 day-' p.o. x 7) and
Adr (35 mgm-2 on day 8) starting on days 1, 15, 29, 50 and
71. All patients were then evaluated for response to induction
therapy. Continuation therapy consisted of vincristine
(1.5mgm-2 every week x 11, maximum 2mgdose-') and
dactinomycin (1.5 mgm-2 every 2 weeks x 6, maximum
2 mg dose-') followed by a further six cycles ofCy-Adr given
at 3-week intervals. Those with metastatic disease then
received a further 11 weeks of vincristine and dactinomycin
as shown above.
RT was delayed until induction therapy was completed
and when delivered was given to limited ports based on
post-induction residual lesions. Patients with pulmonary
metastases at diagnosis who achieved complete responses
with Cy-Adr induction did not receive pulmonary RT. The
dose of RT delivered depended on response to induction
chemotherapy and surgical resectability of residual lesions.
Of the 21 patients with metastatic tumour, only two failed
to achieve a good response to chemotherapy induction. The
5-year disease-free survival (DFS) is 38% and survival (S) is
52% with one relapse occurring beyond 5 years.
Of the 59 patients with localised disease, only four failed to
achieve an excellent response to induction chemotherapy.
The overall 5-year DFS and S for all 59 patients is 61% and
78% respectively.
The size ofthe primary lesion at diagnosis was a significant
factor in whether or not local control and therefore DFS was
maintained. Of 29 patients with lesions less than 8cm in
diameter at diagnosis 27 achieved CR, 21 are disease-free and
25 survive. Eight patients received no RT, 18 low dose RT
(three local and two metastatic relapses) and one standard
dose RT (one metastatic relapse). Of the 27 achieving CR,
three relapsed in the local site and three in a metastatic site
for a 5-year DFS of 72% and a S of 83%.
Of the 30 patients with lesions greater than 8 cm at diag-
nosis, 28 achieved CR, 15 remain free of disease and 20
survive. Six patients received no local RT (two metastatic
relapses), 16 received low dose RT (five local, four local plus
metastatic relapses), and six received standard dose RT (three
local relapses). Of the 28 achieving CR, eight relapsed in the
local site, four in the local plus metastatic sites, and two in a
metastatic site only for a 5-year DFS of 53% and S of 68%.
The difference between the local control rate in small
lesions versus large lesions is significantly different
(P = 0.025). Local recurrences occurred in the centre of the
radiation port in 14 of 15 cases indicating that the small
ports of RT delivered did not contribute to the loss of local
control.
Results of this study suggest: (1) low doses of Cy-Adr are
very effective induction therapy in previously untreated
patients with ES; (2) relatively non-aggressive chemotherapy
delivered for 10 months results in excellent control of micro-
metastatic tumour in that only five of 55 responding patients
with localised disease relapsed in an isolated metastatic site;
(3) in small lesions, therapy as delivered in this study pro-
vides disease control as good as or better than that reported
with more aggressive therapy, and dose so with minimal
toxicity; (4) in larger lesions, therapy as delivered is com-
parable to other reported studies but as with other studies
control is not adequate; (5) markedly limiting the port of RT
does not result in 'marginal miss' recurrences and hopefully
will decrease long-term growth problems in survivors.
Ewing's sarcoma in children and adolescents: update of the
German GPO-CESS studies
H. Jurgens
Universitatskinderklinik, Abteilungfur Hamatologie und
Onkologie, Moorenstr. 5, D-4000 Dusseldorf, FRG.
Since 1981 the German Society of Paediatric Oncology has
conducted two consecutive trials for treatment of primary
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of four 9-week combination chemotherapy cycles with vin-
cristine, actinomycin D, cyclophosphamide and adriamycin.
Local control was postponed until the second cycle was
completed and consisted of either radical surgery with com-
plete resection of the tumour-bearing compartment, intra-
compartmental surgery followed by 36 Gy radiation, or
radiation only. Patients with central tumours received
50-60Gy radiation, whilst patients with extremity lesions
were randomised for 46 vs 60Gy tumour dose.
From January 1981 until February 1985, 93 protocol
patients were entered, the characteristics represent the known
age, sex and skeletal distribution of Ewing's sarcoma.
To date, 42 of the 93 patients have relapsed; the disease-
free survival according to Kaplan-Meier was 54% at 8
years. Of 42 patients with recurrence, only six salvageable;
they remain in second remission; the overall survival by
Kaplan-Meier analysis was 60% at 8 years. For local
therapies only, disease-free survival was 68% in patients with
surgery followed by radiation, 54% in patients with surgery, and 43% in patients with radiation only. This is explained by
a different pattern of site of failure; the proportion of local
failures was 14% for the whole group, 3% in patients with
surgery, 14% in patients with surgery followed by radiation,
and 22% in patients with radiation. The combined rate of
local and systemic failures was 11% for the whole group of
patients, 3 /t both for patients with surgery and those with
surgery followed by radiation, but 25% in patients with
radiation. Using Cox multivariate regression analysis, the
prognosis for patients with small tumours, defined as less
than 100 ml tumour volume, was 69% compared to 31% in
patients with large tumours.
Patients with surgery were evaluable for histological re-
sponse to chemotherapy. Of 42 patients with a favourable
response, 11 have relapsed. The Kaplan-Meier disease-free
survival rate is 73% after 8 years. In comparison, eight out
of 17 patients with poor response relapsed, resulting in a
Kaplan-Meier disease-free survival of 35%. Favourable re-
sponse was defined as less than 10% viable tumour in the
surgical specimen.
In the follow-up study (CESS86) the intensive
chemotherapy was stratified according to the risk of relapse. Patients with standard risk tumours, defined as small ex-
tremity tumours, were continued on the same regimen, whereas patients with high risk tumours, defined as large extremity or central tumours, received a more aggressive chemotherapy regimen, where conventional doses of cyclo-
phosphamide were replaced by high dose ifosfamide. In addi-
tion, local control was moved to week 9 after the first rather
than the second cycle of chemotherapy. In order to secure
local control following radiation, the compartment dose was
increased from 36 to 45Gy. Also patients were randomised
for conventional fractionation of radiation vs a new scheme
of hyperfractionated accelerated split-course radiotherapy, administered in combination with chemotherapy. The characteristics of 100 patients entered into the new
trial since January 1986 are comparable to the previous series, with the exception of a higher number oflarge, partic- ularly central tumours. At 3 years, the predicted disease-free
survival for patients with large tumours has significantly improved, and is at 65% compared to 31% in the previous trial.
From the experience of these two consecutive trials it is
concluded that tumour load and responsiveness to
chemotherapy determine the prognosis of Ewing's sarcoma,
that better results are obtained with more intensive
chemotherapy, and that radiotherapy should be limited to
small chemosensitive tumours in order to secure local con-
trol.
Ewing's sarcoma: United Kingdom Children's Cancer Study
Group Results
A.W. Craft
The Children's Department, Royal Victoria Infirmary, Queen
Victoria Road, Newcastle upon Tyne, UK.
The first UKCCSG Ewing's tumour study (ET-1) was one of
the initial protocols developed by the group after its forma-
tion in 1977, and the aims were firstly to design a protocol
based on the current best available information, and secondly
to try to co-ordinate the care of patients with Ewing's
tumour. Prior to 1977 there had been no such co-ordination
ofcare for these patients, and they had not been entered into
therapeutic studies. The study was open to patients of any
age with biopsy-proven Ewing's tumour. They must have had
no prior chemo- or radiotherapy. Patients with metastases at
diagnosis were eligible. Pre-treatment evaluation included
biopsy of primary bone tumour, bone marrow aspirate, chest
X-ray and whole lung tomography, skeletal survey, and
radioisotope bone scan.
Between 1978 and 1986, 152 children were registered for
the study. Ten of these were excluded, five because they did
not have Ewing's tumour when the histology of the original
biopsy was reviewed; four were treated on another protocol,
and one had radiotherapy as initial therapy prior to entry to
the ET-1 chemotherapy protocol. There remained 142
patients eligible for analysis. All have been followed up,
either to death or to 1989. None was lost to follow-up. At
the time of diagnosis, 115 (81%) were aged 15 years or less,
and 27 (19%) were aged over 15 years. There were 74 males
(52%). Thirty-one had surgical excision of the primary
tumour.
Patients received vincristine 2 mg m-2, adriamycin
50 mg m-2, and cyclophosphamide 1,000 mg m-2 on day 1.
On days 8 and 15 they received vincristine 2 mg m-2, on days
22, 29, 36 and 43, vincristine 2 mg m-2 and cyclophos-
phamide 400 mg m-2 were given. Radiotherapy was given on
days 15-43. On day 64, vincristine 2 mgm2, adriamycin
50 mg m2 and cyclophosphamide 600 mg m2 (VAdC) was
given, and on day 85 vincristine 2mgm-2, actinomycin D
1.4 mg m2, cyclophosphamide 600 mg m-2 (VAC) was
given. Alternating VAdC and VAC every three weeks was
given for 2 years. Actinomycin D was substituted for
adriamycin after a total accumulated adriamycin dose of
300 mg m2. If a good clinical response to VAdC was
obtained, a second or third course could be given before
radiotherapy.
The radiotherapy progamme was given as follows. In the
long bones, the initial fields included the whole bone at
45 Gy + 1,200 Gy boost to the tumour. In the spine, the field
included vertebrae above and below the tumour - a dose of
40 Gy was given. In the ribs, the field included the vertebral
body to a dose of 25 Gy. In the pelvis, the field included at
least the hemipelvis and whole sacrum - 30 Gy + 15 Gy
boost to tumour.
Surgery could be undertaken at the discretion of the
clinician.
Of the 152 patients entered into the first trial, 142 were
analysable. Of these, 22 had metastases at diagnosis, and 120
did not. In the metastatic group, two had proximal disease
and both died; 14 had distal disease, and 12 of these died;
five had axial disease, of whom one survives. In the patients
free of metastases, 27 had proximal disease and 12 died; 31
had distal disease and 13 died; 62 had axial disease and 32
died.
Thus the survival for patients with no metastases was 41%,
but for those with metastases 11 %. Survival was better for
girls than boys, for those under the age of 15, and for those
having proximal and distal primary sites. Poor survival for
axial tumours was due not only to the increased rate of local
recurrence, but also to metastatic disease. Surgery was
increasingly used during the period of study, and improved
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The second protocol followed this study and was a single-
armed, non-randomised study in Ewing's tumour of bone
utilising vincristine, adriamycin, actinomycin D and ifos-
famide, and either surgery and/or radiotherapy as a definitive
treatment for the primary tumour. The aims were to achieve
the best possible cure rate for patients with Ewing's sarcoma,
to determine whether it was possible to grade histological
response of the primary tumour and relate this to outcome,
to assess the feasibility of surgery for all cases, to determine
whether the dose of radiotherapy can be reduced in those
patients who have surgery, and to assess the response rate
and toxicity of IVAD/IVA chemotherapy. Eligible patients
included all those who had biopsy-proven Ewing's sarcoma
of bone, those who were 30 years of age or younger, who
had had no prior local therapy other than biopsy, and
patients with metastases.
Patients started therapy with 'IVAD3' at 3-weekly inter-
vals. IVAD3 was: ifosfamide 3 mg m-2 daily for 3 days;
mesna 3 mg m-2 daily for 3.5 days; vincristine 2 mg m-2
(2 mg max.) on day 1 only; adriamycin 20 mg m-2 daily for 3
days.
At the end of this therapy they were considered for
surgery. Those who had had no surgery or biopsy only were
treated with radiotherapy and vincristine 2 mg m-2 (max.
2 mg) and cyclophosphamide 300mgm2. Those who had
surgery and a complete resection had no radiotherapy. Those
who had had an incomplete resection had radiotherapy and
vincristine and cyclophosphamide in the doses given above.
All patients subsequently received 'IVAD2' for three
courses at 3-weekly intervals, and finally IVA at 2-weekly
intervals until the 52nd week of the programme. IVAD2 was:
ifosfamide 3 mg m-2 daily for 2 days; mesna 3 mg m-2 daily
for 2.5 days; vincristine 2 mg m-2 (max. 2 mg) on day 1 only;
adriamycin 30 mg m-2 daily for 2 days. IVA was as above,
but actinomycin D 1.5 mg m-2 on day 1 only instead of
adriamycin.
To date 82 patients have been entered into this study. The
features of the cohort were very similar to those of the first,
except that approximately double the number of the patients
in the latest study had metastases on presentation compared
with the first study. This may, however, have represented
better staging techniques. With respect to treatment, 26% of
patients in the first study had surgery, while 80% did so in,
the second. The acute toxicity of the second programme is
severe, but is tolerable and no serious cardiotoxicity has been
seen. The majority of patients who had comprehensive renal
assessment at the end of treatment have evidence of
glomerular and/or tubular toxicity. It is too early yet to give
survival data.
Ifosfamide containing chemotherapy in localised Ewing's
sarcoma. No benefit on disease-free survival (when compared
to cyclophosphamide regimen) but cardiac toxicity
0. Oberlin, M. Brunat-Mentigny, F. Pein, M.C. Demaille,
J.M. Zucker, P. Lutz, J.P. Vannier, P. Boutard, C. Behar,
M. Jullien, P. Terrier & J. Lemerle
A Co-operative Study ofthe French Society ofPaediatric
Oncology
Between 1978 and 1982, 96 children with localised Ewing's
sarcoma were treated wity cyclosphosphamide containing
initial chemotherapy, radiotherapy maintenance chemo-
therapy. At 3 years, the disease-free survival was 52% and
remains stable 3 years later.
In the subsequent study (1984-1987) cyclophosphamide
was replaced by ifosfamide with the aim of improving the
efficiency of the chemotherapy. Initial chemotherapy was
three cycles of IVA (IFO 3 g m-2 Dl-D2 in infusion over 3
hours, vincristine 1.5 mg m-2 Dl, actinomycin D 750fig m-2
DI-D2-D3) alternating every 3 weeks with three cycles of
IVAd (IFO 3 g m 2 Dl-D2, vincristine 1.5 mg m 2 D1,
adriamycin 60 mgm-2 DI, in pulse). Radical surgery was
then considered for each case. Radiotherapy dose had to be
decided according to the surgery: 40 Gy in patients who had
complete surgical resection of their tumour, 45-60Gy in
patients who had incomplete or no surgery. Maintenance
chemotherapy consisted of alternating IVA (with ifosfamide)
and VAd (without ifosfamide) given for a total duration of
treatment of 1 year.
In May 1987, 68 patients with localised tumour had
entered the study, coming from 22 centres in France and
Switzerland. The age ranged from 3 to 18 years (median 11.5
years). Fifty-two per cent of the tumours were located on
axial bones, and 48% on limbs. Thirty-nine patients could
undergo surgical resection of their tumour with conservative
procedure in 34 cases. By May 1989, 31 failures had been
observed: one initial progression, 14 local relapses, and 16
metastases. So the disease-free survival at 36 months is only
50% and quite similar to the rate observed in the first study.
In the ifosfamide study, we observed congested heart
failure in three patients, occurring 6-8 weeks after the end of
therapy and cumulative doses of adriamycin ranging from
420 to 480 mg m 2. Two of these patients died, one is alive
after heart transplantation. (In the cyclophosphamide study,
a single case of moderate cardiac failure was observed, after
cumulative dose 240 mg m-2 of adriamycin.) Beside this
acute major toxicity, in the ifosfamide study, seven patients
had significant echocardiographic abnormalities. The role of
the modes of administration of the drugs over short periods
was considered.
Although the number of patients is not very large, the
results of this study suggest that ifosfamide is not more
effective than cyclophosphamide in Ewing's sarcoma and
may enhance the cardiotoxity of adriamycin.
Radiotherapy in the local control of Ewing's sarcoma
P.N. Plowman
Department ofRadiotherapy, St Bartholomew's Hospital and
Hospitalfor Sick Children, London, UK.
Although one large study in 1981 by the American Ewing's
sarcoma intergroup suggested good local control with
chemoradiotherapy alone, subsequent studies with longer
follow-up have not experienced such good overall local con-
trol rates. We have analysed a series of 67 patients treated in
these hospitals between 1973 and 1984. Radiotherapy was
employed with or without surgery in 67 patients and resulted
in a local control rate of 55% only; complete excision of the
bone seemed beneficial. There was a marked variation in
control rates depending on the site of the primary lesion:
limb 85%, rib 53%, pelvis 31%, other sites 33%. Primary
tumours greater than 10 cm in diameter at presentation were
significantly less likely to be locally controlled. These and
other data demonstrating local relapse before overwhelming
systemic metastases argue for local surgery as a part of
definitive primary therapy for the primary in non-metastatic
cases.
Radiotherapy maintains its important role in primary
therapy and lessons learnt in the 1980s include the facts that
doses beyond 55 Gy are not attended by higher local control
rates (but do predispose to later, worse morbidity and per-
haps increased second sarcoma risk), and that sparing an
epiphysis away from the primary in a long bone may be a
safe radiotherapeutic procedure.
Future trials in Ewing's sarcoma
R.L. Souhami
Department ofOncology, University College & Middlesex
School ofMedicine, London, UK.
The problems in treatment of Ewing's sarcoma have been
identified through a series of non-randomised 'observational'330 WORKSHOP ON EWING'S SARCOMA
studies which have taken place over the last 15 years. These
studies have been able to identify local control rates of the
primary tumour and long term survival. Retrospective
analysis of the data has identified good and poor risk prog-
nostic groups and has recently related survival to histological
response. It is clear that, in many of the studies, patients with
small volume disease, particularly in the distal bones, have a
good prognosis with present chemotherapy regimens. In con-
trast, patients with large volume disease, particularly in the
femur, chest wall and pelvis, have a high risk of local recur-
rence and of systemic metastases. The risk of local recurrence
persists for five or six years. It appears that chemotherapy
has, in relapsing patients, delayed recurrence rather than
prevented it.
The problem with these studies has been that it is not
possible to say with certainty which chemotherapy regimens
are the most effective, and which strategies should be
adopted for improving local recurrence rate. Randomised
studies are necessary to make some assessment of these prob-
lems.
The difficulty in Ewing's sarcoma is that the disease is rare
and different strategies may be needed for patients who are
already doing well with current treatment policies, compared
with those who are at risk of failure. It seems unlikely that
improvement in survival of more than 15% is to be expected
by intensification, or alteration, of treatment, but such im-
provements are well worthwhile and studies need to be
designed in order to detect them. If we take overall survival
of 60% as being representative of Ewing's sarcoma in
general, to improve this survival to 70% will require a ran-
domised trial of 562 patients (80% power, 5% significance);
an improvement to 80% will require 137 patients to be
randomised, and 90% will require 61 patients. An improve-
ment of survival from 65% to 80% would require 226
patients to be randomised. Randomised trials containing
250-300 patients are not impossible in Ewing's sarcoma, but
would inescapably mean a high degree of national and inter-
national co-operation. Nonetheless, large groups such as the
MRC/UKCCSG admit 50-60 patients into studies each
year, and it would only require two or three such groups to
join to be able to make important contributions to manage-
ment.
What questions might realistically be posed in intergroup
studies of this kind?
1. In good prognosis patients (a term which would require
definition) it is important to assess whether the chemotherapy
introduced by the St Jude's group, which is relatively non-
toxic and of low intensity, is really the equivalent of, or
better than the more intensive programmes currently used by
the West German or English groups. This can only be
assessed in a randomised setting, and the result would be of
practical importance for many of our patients.
2. For the poor prognosis patients, studies can be set up in
which attempts to assess local control may be made. Such
trials might, in unresectable lesions, assess radiotherapy given
concomitantly with chemotherapy or sequentially after induc-
tion chemotherapy. Such an approach could also be tried in
metastatic cases where surgical resection is considered less
important. Similarly, in resectable lesions, an assessment
could be made of whether radiotherapy is better given before
or after surgery. In these patients an alternative study might
be to determine whether the dose of radiation required to
achieve local control needs to be as high as 50 Gy or can be
reduced following successful resection. These questions of
dosage are of importance both in functional results and in
terms of second cancers in irradiated bone, which is a serious
long term problem for bone radiation in Ewing's sarcoma.
Studies on local control rates would be best done in a
randomised phase II setting, and far fewer patients would be
needed than are required to assess survival. Such studies are
eminently feasible among groups working in collaboration,
but it would probably be necessary to restrict the col-
laborators to five or six major centres in order to ensure
quality control of surgery and radiation. These studies are
likely to generate data from which future randomised trials
can be planned.
3. Patients with metastases, particularly in bones, have
very bad prognosis and phase II studies can be designed
which allow us to ask questions concerning dose intensity of
chemotherapy. Such studies might involve the use of
haemopoietic growth factors or late intensification schemes
using high-dose chemotherapy and autologous bone marrow
transplantation.
Collaborative intergroup studies of this kind also permit
co-operation between histologists in defining the importance
of the neuroectodermal phenotype and its relationship to
prognosis. It will also allow pathologists to agree on scoring
systems for necrosis following chemotherapy. Other col-
laborative studies would allow comparison of CT scan
estimation of tumour volume and its relationship to prog-
nosis and multivariate analysis of prognostic variables in
large data sets. These latter aspects of collaboration could
proceed even without collaborative clinical studies, but the
great advantage of clinical programmes, particularly when
randomised, is that they generate close working relationships
and enthusiasm and excitement about the outcome of the
studies.
Summary and conclusions
C.R. Pinkerton & J.S. Malpas
The histogenesis of Ewing's sarcoma still represents
something of a mystery, but it seems likely that a tumour of
common origin presents either in an undifferentiated form as
a classical Ewing's sarcoma, or with varying degrees of
neural differentiation, the most differentiated being the clas-
sical primitive neuroectodermal tumour PNET. Immuno-
chemical and cytogenetic studies may help to elucidate their
relationship. International co-operation between histologists
to provide adequate numbers to be able to produce definitive
statements are now necessary.
It is essential that all modern investigative techniques be
used in assessing and staging Ewing's sarcoma, as it is evi-
dent that the prognosis for metastatic disease compared with
earlier stages is very much worse. Although new methods
such as MRI have not made a very significant contribution
to this problem, MRI does give additional information, help-
ing to delineate the primary tumour and assess the amount of
bone-marrow disease.
The large national studies on the treatment of Ewing's
sarcoma which were reported were largely observational. The
rarity of the tumour precludes randomised trials. The only
possibility of answering the numerous questions that these
studies have now raised will be through co-operative trials,
and it is thought that this group should endeavour to initiate
them.
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